6,334 Shares in Natera, Inc. $NTRA Bought by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 6,334 shares of the medical research company’s stock, valued at approximately $1,719,000.

Other large investors have also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC grew its holdings in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC raised its stake in shares of Natera by 68.3% in the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth raised its stake in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Natera during the second quarter worth about $298,000. Finally, WINTON GROUP Ltd acquired a new position in Natera in the second quarter worth about $558,000. 99.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the transaction, the chief executive officer directly owned 108,743 shares of the company’s stock, valued at $24,035,465.29. The trade was a 27.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the transaction, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 181,045 shares of company stock valued at $41,330,968. Corporate insiders own 5.05% of the company’s stock.

Natera Price Performance

Shares of NASDAQ NTRA opened at $332.03 on Monday. The firm’s 50-day moving average price is $274.24 and its two-hundred day moving average price is $229.38. Natera, Inc. has a 52-week low of $157.43 and a 52-week high of $333.56. The stock has a market capitalization of $47.86 billion, a P/E ratio of -244.14 and a beta of 1.51.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business’s revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.74) earnings per share. As a group, equities research analysts expect that Natera, Inc. will post -1.02 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on NTRA. Morgan Stanley reissued an “overweight” rating and issued a $355.00 price objective on shares of Natera in a report on Monday, August 10th. Wolfe Research started coverage on Natera in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. BTIG Research boosted their price target on Natera from $290.00 to $320.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wells Fargo & Company upped their price target on Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Finally, Evercore restated an “outperform” rating and set a $300.00 price objective on shares of Natera in a research note on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $319.38.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.